| Literature DB >> 33471201 |
Zhong Li1, Shiqi Xiang1, Eileen N Li1,2, Madalyn R Fritch1, Peter G Alexander1, Hang Lin1,2, Rocky S Tuan3,4,5.
Abstract
Musculoskeletal injuries and associated conditions are the leading cause of physical disability worldwide. The concept of tissue engineering has opened up novel approaches to repair musculoskeletal defects in a fast and/or efficient manner. Biomaterials, cells, and signaling molecules constitute the tissue engineering triad. In the past 40 years, significant progress has been made in developing and optimizing all three components, but only a very limited number of technologies have been successfully translated into clinical applications. A major limiting factor of this barrier to translation is the insufficiency of two-dimensional cell cultures and traditional animal models in informing the safety and efficacy of in-human applications. In recent years, microphysiological systems, often referred to as organ or tissue chips, generated according to tissue engineering principles, have been proposed as the next-generation drug testing models. This chapter aims to first review the current tissue engineering-based approaches that are being applied to fabricate and develop the individual critical elements involved in musculoskeletal organ/tissue chips. We next highlight the general strategy of generating musculoskeletal tissue chips and their potential in future regenerative medicine research. Exemplary microphysiological systems mimicking musculoskeletal tissues are described. With sufficient physiological accuracy and relevance, the human cell-derived, three-dimensional, multi-tissue systems have been used to model a number of orthopedic disorders and to test new treatments. We anticipate that the novel emerging tissue chip technology will continually reshape and improve our understanding of human musculoskeletal pathophysiology, ultimately accelerating the development of advanced pharmaceutics and regenerative therapies.Entities:
Keywords: Biological induction; Biomaterial; Disease modeling; Drug testing; Growth factors; Microphysiological system; Organoid; Regenerative medicine; Stem cells; Tissue chip
Mesh:
Year: 2021 PMID: 33471201 PMCID: PMC8049527 DOI: 10.1007/164_2020_377
Source DB: PubMed Journal: Handb Exp Pharmacol ISSN: 0171-2004